Sydney, 26 October 2018: Noxopharm (ASX:NOX) today releases its Appendix 4C for the quarter ended 30 September 2018, as well as providing guidance on the next 12-18 months.
This report is presented in the context of the Company’s overriding objective which is to bring its lead pipeline drug, Veyonda, to market in 2022 as a standard companion drug to radiotherapy in the management of many forms of cancer.
Current clinical studies in men with progressive, late-stage prostate cancer point to a combination of Veyonda and radiotherapy providing patients with improved outcomes over standard care. Accordingly, the Company believes that Veyonda has the potential to transform the practice, not just of the treatment of prostate cancer, but of cancer therapy in general and in so doing become one of the most widely-used drugs in oncology.
For further information please download PDF attached:
Download this document
